The latest T1D content
Research that matters
Our daily questions
Continue with Google
Continue with Facebook
Now enrolling adults with type 1 diabetes in a clinical trial for an investigational oral medication.
T1D Exchange is helping vTv Therapeutics find participants for their clinical trial evaluating a drug called cadisegliatin (also known as TTP399). TTP399 is an investigational oral medication that supports the liver’s ability to store glucose, which may help reduce the risk of hypoglycemia (low blood sugar) and lower A1C levels.
About the Investigational Drug
The study drug, called cadisegliatin, or TTP399, is an investigational medication for adults living with T1D. TTP399 is an oral medication which is designed to support the liver in more effectively storing glucose. This may help reduce the risk of hypoglycemia and lower your A1C.
Share this information with friends, family, or your doctor.
T1D Exchange is not a sponsor and is not administering this clinical trial, nor are we implying that you will qualify. We are sharing this research opportunity with you so you can decide whether to seek more information or participate.
ELIGIBILITY CRITERIA
vTv Therapeutics is looking for individuals who:
- Are over the age of 18
- Have been living with T1D for at least 5 years
- Have an A1C below 9.5% at the start of the clinical trial
- Have had at least one of the following in the past 2 months:
-
- A glucose meter or CGM reading below 54 mg/dL
-
- A severe low requiring help from another person
* The guidelines listed above are the primary eligibility criteria for this study. Only the clinical trial research staff can determine if you meet all eligibility criteria for this study.
See If You Qualify
Step 1: Complete a brief questionnaire to determine if you may be a good fit for this clinical trial. You will also be asked if you agree to have your contact information shared with the clinical trial staff.
Step 2: If your answers in the eligibility screener suggest you may qualify, your local study site coordinator will contact you. Your local study site coordinator will ask follow-up questions to confirm your eligibility for this trial. They will also provide additional information about this research opportunity and, if you qualify, give you the option to enroll.
To protect your privacy, we will not share your contact information with the study staff unless you sign the Informed Consent Form at the beginning of the eligibility screener.
WHAT TO EXPECT
Participants in this clinical trial will be assigned at random to one of three groups. Two groups will receive TTP399 at different dosages. One group will receive a placebo. All participants will receive insulin. Each group will take their assigned study medication for 26 weeks. Participants must take the assigned study drug twice daily at mealtimes. Participants will also be given a Dexcom G7 CGM to wear throughout the trial.
The study will last approximately 9 months and requires up to 11 in-person and 11 virtual visits.
The clinical trial research staff will communicate other requirements.
Qualified participants will receive payment for time and travel.
DIRECTORY OF SITES BY STATE
Headlands Research California, LLC AMCR
625 West Citracado Parkway
Suite 112
Escondido, CA 92025
Scripps Whittier Institute for Diabetes
9898 Genesee Ave
6th Floor
La Jolla, CA 92037
Denver Endocrinology Diabetes and Thyroid Center
799 E. Hampden Ave
Suite 525
Englewood, CO 80113
ALL Medical Research, LLC
9700 Stirling Rd.
Suite 103
Cooper City, FL 33024
Metabolic Research Institute, Inc.
1515 North Flagler Drive
Suite 440
West Palm Beach, FL 33401
Atlanta Diabetes Associates
1800 Howell Mill Rd
Suite 450
Atlanta, GA 30318
East Coast Institute for Research – Canton
125 Oakside Court
Suite 301
Canton, GA 30114
Centricity Research – Columbus
2425 Brookstone Centre Parkway
Columbus, GA 31904
The Jones Center Clinical Research
265 Sheraton Blvd
Macon, GA 31210
Endocrine Research Solutions, Inc
1475 Holcomb Bridge Road
Suite 129
Roswell, GA 30076
Iowa Diabetes and Endocrinology Research Center
4201 Corporate Drive
Suite 100
West Des Moines, IA 50266
University of North Carolina at Chapel Hill
800 Eastowne Drive, Suite 208
Chapel Hill, NC 27514
Lucas Research, Inc.
623 North 35th Street
Morehead City, NC 28557
Vector Clinical Trials – Reno
5444 Reno Corporate Drive
Reno, NV 89511
Jacobi Medical Center
1400 Pelham Parkway South
Bronx, NY 10461
Velocity Clinical Research – Medford
3121 Signature Court
Medford, OR 97504
University of Pennsylvania
3400 Civic Center Blvd.
11 South Room 11-102
Philadelphia, PA 19104
Texas Diabetes and Endocrinology, P.A
6500 N. Mopac Expwy
Bldg 3 Ste 200
Austin, TX 78731
Velocity Clinical Research – Dallas
7777 Forest Lane
Suite C-685
Dallas, TX 75230
Southern Endocrinology Associates
1621 North Belt Line Road
Suite A
Mesquite, TX 75149
Diabetes & Glandular Disease Clinic
5107 Medical Dr
Research Department
San Antonio, TX 78229
Consano Clinical Research
4118 Pond Hill
Bldg., #300
Shavano Park, TX 78231
University of Washington Medical Center
4225 Roosevelt Way NE
Suite 101
Seattle, WA 98105
